Illumina Launches New Reagent Kits for the MiSeq® System

  Illumina Launches New Reagent Kits for the MiSeq® System

   Latest Milestone Doubles Sequencing Output to 15Gb, Enables Applications
                          Including Exome Sequencing

Business Wire

SAN DIEGO -- August 19, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced the availability of its newest
reagent kits for the MiSeq, the industry’s most accurate and easiest-to-use
benchtop sequencer. The improved chemistry doubles sequencing output to 15
gigabases (Gb) by increasing the number of sequencing reads (up to 25 million
reads) and overall read length (up to 2x300 base pairs). These innovations
enable researchers to perform new applications including exome sequencing on
the MiSeq.

In addition, increased sequencing reads will support transcriptome
applications such as mRNA sequencing and will offer higher throughput capacity
for gene expression profiling with Illumina’s TruSeq Targeted RNA Expression
assay. The benefits of increased paired-end read lengths include improving the
quality of genome assemblies and advancing applications that require longer
read lengths, such as metagenomics and human leukocyte antigen (HLA) typing.

“The new MiSeq kits are another example of how we are focused on continually
improving the performance and value of our sequencing platforms for our
customers,” said Christian Henry, Senior Vice President and General Manager of
Illumina’s Genomic Solutions business. “The latest MiSeq system enhancements
deliver the highest data quality and will open up new applications for
researchers in markets as diverse as cancer, genetic disease, microbiology,
agriculture and forensics.”

Added Dr. Ellen Heitzer of the Institute for Human Genetics, Medical
University of Graz in Austria, “As a beta customer, we have seen even more
robust MiSeq performance with the new chemistry, including the ability to pool
more samples for our circulating tumor assay. We’ve also seen excellent
sequencing quality, with almost 90 percent of clusters passing the filter and
96 percent of reads with a quality score greater than 30. In addition, the
longer read length will facilitate the identification of translocations and
fusion genes for our target resequencing approaches."

The new MiSeq reagent kits are now shipping, including a 600-cycle kit and a
150-cycle kit. For more information visit, www.illumina.com/MiSeq.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.